Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy by Clara Bodelon et al.
RESEARCH ARTICLE Open Access
Leukocyte telomere length and its
association with mammographic density
and proliferative diagnosis among women
undergoing diagnostic image-guided
breast biopsy
Clara Bodelon1,10*, Christopher M. Heaphy2, Alan K. Meeker3, Berta Geller4, Pamela M. Vacek5, Donald L. Weaver6,
Rachael E. Chicoine7, John A. Shepherd8, Amir Pasha Mahmoudzadeh8, Deesha A. Patel1, Louise A. Brinton1,
Mark E. Sherman9 and Gretchen L. Gierach1
Abstract
Background: Elevated mammographic density (MD) is a strong breast cancer risk factor but the mechanisms
underlying the association are poorly understood. High MD and breast cancer risk may reflect cumulative exposures
to factors that promote epithelial cell division. One marker of cellular replicative history is telomere length, but its
association with MD is unknown. We investigated the relation of telomere length, a marker of cellular replicative
history, with MD and biopsy diagnosis.
Methods: One hundred and ninety-five women, ages 40–65, were clinically referred for image-guided breast
biopsies at an academic facility in Vermont. Relative peripheral blood leukocyte telomere length (LTL) was
measured using quantitative polymerase chain reaction. MD volume was quantified in cranio-caudal views of the
breast contralateral to the primary diagnosis in digital mammograms using a breast density phantom, while MD
area (cm2) was measured using thresholding software. Associations between log-transformed LTL and continuous
MD measurements (volume and area) were evaluated using linear regression models adjusted for age and body
mass index. Analyses were stratified by biopsy diagnosis: proliferative (hyperplasia, in-situ or invasive carcinoma) or
non-proliferative (benign or other non-proliferative benign diagnoses).
Results: Mean relative LTL in women with proliferative disease (n = 141) was 1.6 (SD = 0.9) vs. 1.2 (SD = 0.6) in those
with non-proliferative diagnoses (n = 54) (P = 0.002). Mean percent MD volume did not differ by diagnosis (P = 0.69).
LTL was not associated with MD in women with proliferative (P = 0.89) or non-proliferative (P = 0.48) diagnoses.
However, LTL was associated with a significant increased risk of proliferative diagnosis (adjusted OR = 2.46, 95 % CI:
1.47, 4.42).
Conclusions: Our analysis of LTL did not find an association with MD. However, our findings suggest that LTL may
be a marker of risk for proliferative pathology among women referred for biopsy based on breast imaging.
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Background
Mammographic density (MD) is a radiological reflection
of the fibroglandular content of the breast, which histo-
logically corresponds to both increased epithelium and
stroma [1]. Epidemiologic investigations have established
that increased MD is a strong breast cancer risk factor
[2], but the mechanisms that mediate the underlying risk
are poorly understood [1].
Both environmental and biologic factors are thought
to be responsible for the variations in breast tissue com-
position that are reflected in inter-individual differences
in the extent of MD [3]. Factors associated with lower
MD include increasing age, elevated body mass index
(BMI) [3], and tamoxifen use [4], whereas nulliparity,
later age at first birth, premenopausal status [5], meno-
pausal hormone therapy use [6], and family history of
breast cancer [7] are related to higher MD. Epidemio-
logical factors associated with higher MD suggest that
MD is related to cumulative exposures to hormones,
growth factors or other factors that promote epithelial
cell proliferation [3, 8]. However, biopsies of women with
high MD vary with regard to severity of disease and epi-
thelial content, and most women with high MD do not
develop cancer. Accordingly, identifying which women
with high MD harbor proliferative lesions that are associ-
ated with increased breast cancer risk is important. In
contrast to markers that provide only a snapshot in time,
telomere length captures replicative history, and therefore
might reveal an underlying relationship with MD, another
cumulative marker of risk.
Telomeres are nucleoprotein structures composed of
repetitive DNA sequences (TTAGGG) and the shelterin
protein complex. They cap the ends of chromosomes and
help maintain genetic stability. TTAGGG repeats are lost
during cell division, shortening telomeric DNA. When the
telomeric DNA reaches a critical length, cells may
undergo senescence, apoptosis or, if tumor suppressive
mechanisms are abrogated, neoplastic transformation.
Shorter telomeres have been observed in breast epithelial
tumor cells compared with adjacent non-malignant tissue
[9], with the shortest telomeres associated with the most
aggressive subtypes of breast cancer [10]. In surrogate
tissues (e.g., blood cells), associations between telomere
length, breast cancer risk factors [11–16] and breast
cancer risk [17–28] have been inconsistent.
As with MD, it has been suggested that shortening of
telomeres could be a consequence of exposures that
drive cell proliferation [29, 30]. We hypothesized that
relative leukocyte telomere length (LTL), which may
reflect cumulative exposures that promote cell division,
may be related to MD. Therefore, we investigated the
relationship between LTL and volume and area MD
measures in a cross-sectional study of women referred
for image-guided breast biopsy. Telomere shortening has
been found to be involved in the early stages of breast
carcinogenesis [29, 31], and therefore may be an indicator
of subsequent malignant transformation. We also ex-
plored associations between relative LTL and proliferative
versus non-proliferative biopsy diagnoses.
Methods
Study population
The National Cancer Institute (NCI) Breast Radiology
Evaluation and Study of Tissues (BREAST) Stamp Project
is a cross-sectional molecular epidemiologic study of
mammographic density undertaken at the University of
Vermont College of Medicine and its affiliated academic
medical center, Fletcher Allen Health Care (FAHC). The
study design and methodology have been described previ-
ously [32]. Briefly, 465 women who were referred for a
diagnostic image-guided breast biopsy were enrolled be-
tween October 2007 and June 2010. Eligible women were
40–65 years of age, had not had breast cancer or received
any cancer treatment, had not undergone breast surgery
within the preceding year, did not have breast implants,
were not taking breast cancer chemoprevention and were
scheduled to have an image-guided breast biopsy.
The study was approved by the NCI Special Studies
Institutional Review Board (IRB) and the University of
Vermont IRB. Participants provided written informed
consent to be part of the study and completed a stand-
ard health history questionnaireA research coordinator
administered a telephone interview to collect additional
health information. On the day of the breast biopsy, a
research coordinator measured participants’ height and
weight, and participants were asked to donate a blood
sample. The informed consent included providing access
to medical records and mammographic images and to
breast pathology specimens not needed for clinical care.
Compensation of $50 was provided to participants who
opted to donate blood (processed and frozen as serum
and blood clot) and/or mouthwash samples (processed
and frozen as buccal cells).
Assessment of pathologic diagnosis
Breast biopsy and surgical pathology reports were
reviewed for all study participants. For the purposes of
this analysis, diagnoses were classified as non-prolifera-
tive (i.e., benign; normal lobules or ducts defined as
sclerotic/atrophied; non-proliferative fibrocystic change;
other discrete non-proliferative benign breast diagnoses)
or proliferative, including both atypical and neoplastic
entities (i.e., ductal or lobular hyperplasia; sclerosing
adenosis; in-situ carcinoma; invasive carcinoma). Infor-
mation about biopsy type and laterality was abstracted
from pathology reports.
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Assessment of mammographic density
Mammograms were acquired on one of six full field
digital mammography systems at FAHC. Raw images
were encrypted and transferred to the University of
California at San Francisco for quantitative volume and
area density assessment. This analysis was restricted to
pre-biopsy cranio-caudal views of the contralateral
breast. For women who underwent bilateral breast biop-
sies, the breast contralateral to the primary pathologic
diagnosis was selected for analysis. If more than one
mammogram was available, then the mammogram taken
closest in time prior to the breast biopsy date was
selected.
Breast density was quantified as an absolute fibro-
glandular tissue volume (cm3) and percent fibroglandu-
lar tissue volume using Single X-ray Absorptiometry
(SXA), as described previously [33]. An SXA breast
density phantom was affixed to the top of the compres-
sion paddle and included in the X-ray field during
mammography examinations. Mammographic grayscale
values were compared to the values of the SXA phan-
tom. Previous estimates of reproducibility for the SXA
test phantoms demonstrated a repeatability standard de-
viation of 2 %, with a ±2 % accuracy for the entire thick-
ness and density ranges [33]. Area measures of density
were estimated as described previously [34], using inter-
active, customized computer-assisted thresholding soft-
ware comparable to other validated methods [35]. One
trained experienced reader [34] measured absolute dense
area (cm2) by setting a pixel threshold for dense tissue
on the images. Percentage mammographic density was
calculated by dividing the absolute dense breast area by
the total breast area and multiplying by 100. For both
area and volume density measures, distributions of dens-
ity measures were examined and images with extreme
values were reviewed visually for validation.
Assessment of relative leukocyte telomere length
Whole blood samples were collected using standard
techniques, allowed to clot for 30 min, and processed at
the FAHC General Clinical Research Center. Samples
were centrifuged at 3000 rpm for 15 min, and the serum
and clot fractions were frozen at −80 °C until shipment
to SeraCare Life Sciences (Gaithersburg, MD), where
they were stored in liquid nitrogen. Leukocyte DNA was
isolated from blood clots at SeraCare using phenol
chloroform extraction methods and quantified at the
Cancer Genomics Research Laboratory (Leidos Builme-
dical Research, Inc., Frederick, MD) with the Quanti-
Fluor® dsDNA System (Promega) according to the
manufacturer’s instructions. DNA in 500 ng aliquots was
sent to Johns Hopkins University School of Medicine,
where quantitative polymerase chain reaction (qPCR)
was used to estimate the ratio of telomeric DNA to that
of a single copy gene (β-globin) as previously described
[36], with the following modifications. Briefly, to remove
potential residual PCR inhibitors, leukocyte DNA was
re-purified using a DNeasy Blood and Tissue column
(Qiagen) and 4 ng of genomic DNA was used in a 25 μl
volume for either the telomere or β-globin reactions;
each sample was run in triplicate. The telomere reaction
mixture consisted of 1× PCR buffer, 1.5 mM MgCl2,
100,000 fold dilution of SyberGreen, 200 nM dNTP mix,
1 % DMSO, 100 nM forward telomere primer (CGGT
TTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGG-
TT), 900 nM reverse telomere primer (GGCTGGC
CTTACCCTTACCCTTACCCTTACCCTTACCCT), and
0.8 U of Platinum Taq polymerase. The reaction pro-
ceeded for one cycle at 95 °C for 5 min, followed by 35 -
cycles at 95 °C for 15 s, and 54 °C for 30 s. The β-globin
reaction mixture consisted of 1× PCR buffer, 2.5 mM
MgCl2, 100,000 fold dilution of SyberGreen, 200 nM
dNTP mix, 2 % DMSO, 300 nM forward β-globin primer
(CACATGGCAAGAAGGTGCTGA), 700 nM reverse β-
globin primer (ACAGTGCAGTTCACTCAG CTG), and
0.5 U of Platinum Taq polymerase. The β-globin reaction
proceeded for one cycle at 95 °C for 5 min, followed by
35 cycles at 95 °C for 30 s, 58 °C for 30 s, and 72 °C for
45 s. Each 96-well plate contained a no template negative
control and two separate 5-point standard curves ranging
from 0.024 to 15 ng using leukocyte DNA. These standard
curves allowed the PCR efficiency to be determined for
each experimental run. Each of the 10 plates also included
three samples isolated from a series of cell lines with
known telomere lengths, ranging from 3 to 15 Kb, as
determined by terminal restriction fragment analysis.
Inclusion of these samples provided an additional quality
control check. The coefficient of variation (CV) for this
cell line series ranged from 1.3 to 6.8 % across plates. Sam-
ples were re-run if the CV of either the telomere or the β-
globin reaction was equal or greater than 5 % or either the
telomere or the β-globin values fell outside the range of
the standard curve. The maximum CVs were 4.8 and
3.9 % for the β-globin and telomere reactions, respectively.
The average β-globin threshold (Ct) value and the telo-
mere Ct value were calculated from the β-globin and the
telomere triplicate reactions, respectively. For each sam-
ple, the telomere of the experimental sample to the single
copy gene (T/S) ratio (−dCt) was calculated by subtracting
the β-globin Ct value from the telomere Ct value. The
relative T/S ratio (−ddCt) was determined by subtracting
the -dCt of the middle samples of the cell lines series from
the -dCt of each unknown sample. The relative T/S ratios
(i.e., mean relative LTL) were used in the analysis.
Analytic population
We restricted the study population to participants who
had SXA volumetric MD measurements, donated blood
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and whose breast biopsies contained terminal duct lobu-
lar units (TDLUs) suitable for assessment of telomere
lengths (analysis ongoing). Of the 465 participants who
consented, 12 were not subsequently biopsied and were
excluded; 338 (75 %) women donated blood and had
clots with a volume ≥1.0 mL, of whom 212 also had
breast tissues available for telomere length assessment.
Twelve women were missing SXA density and were
excluded. Characteristics of the remaining eligible 200
women as compared to and the rest of the participants
in the BREAST Stamp Project were similar with the ex-
ception of BMI, which was lower in the women included
in our analysis (data not shown). Of the 200 women
whose DNA underwent qPCR for relative LTL assess-
ment, two samples failed quality control on two separate
runs and were excluded. In addition, three participants
had a relative LTL that was larger than three standard
deviations from the study population mean and were
also excluded, resulting in a final analytic population of
195 women.
Statistical analysis
Statistical differences in participant characteristics by
biopsy diagnosis (proliferative vs. non-proliferative dis-
ease) were computed using the Wilcoxon rank-sum test
for continuous measures and the χ2 test for categorical
variables, except when values in cells where less than or
equal to 5 in which case the Fisher’s exact test was used.
The Spearman correlation coefficient was computed to
examine the correlation between relative LTL with age
stratified by pathological diagnosis. Logistic regression
was used to compute the association between relative
LTL (continuous) and risk of proliferative disease adjust-
ing for age (continuous) and BMI (continuous), which
are known to be strongly associated with relative LTL.
Relative LTL was transformed using the natural loga-
rithm to improve normality. Multivariate linear regres-
sion was used to estimate the relationship between log-
transformed relative LTL and participant characteristics
adjusting for age (continuous) and BMI (continuous).
Relative LTL was then back-transformed to the original
scale and geometric means are presented. Similarly,
multivariate linear regression was computed to examine
the relationship between MD and relative LTL, adjusting
for the potential confounders of age (continuous) and
BMI (continuous). In sensitivity analyses, we additionally
adjusted for age at first birth (nulliparous, <30, 30+
years) and menopausal hormone therapy use (premeno-
pausal/postmenopausal ever/ postmenopausal never).
Quantitative volume and area density measures were
transformed by taking the square root to approximate a
normal distribution. Relative LTL was modeled as either
binary, by categorizing relative LTL at the median
relative LTL levels in subjects with non-proliferative
diagnoses, or as a log-transformed continuous variable.
Adjusted means of mammographic density measures
were back-transformed by squaring the results. P-values
were two-sided and P ≤ 0.05 was considered statistically
significant. All analyses were performed using the R soft-
ware environment (version 3.0.2).
Results
The majority of participants were diagnosed with prolifer-
ative disease (n = 141) and the remainder had a non-
proliferative biopsy diagnosis (n = 54) (Table 1). Among
women with a proliferative diagnosis, 110 had hyperplasia,
22 in-situ carcinoma and 9 invasive carcinoma. Among
those with non-proliferative diagnoses, 42 had a benign
diagnosis and 12 had other discrete non-proliferative diag-
noses. Seven women with a proliferative diagnosis had
bilateral biopsies. The diagnosis in the breast contralateral
to the primary pathologic diagnosis for these women was
benign for two of them, hyperplasia for four of them and
in-situ carcinoma for one woman. None of the women
with non-proliferative diagnoses had bilateral biopsies.
Compared with women with non-proliferative diagno-
ses, women with proliferative diagnoses tended to be older
(P = 0.005) and were more likely to have used menopausal
hormone therapy (P = 0.039). MD measures did not differ
between women with proliferative versus non-proliferative
diagnoses. On average, relative LTL was similar among
women with different categories of proliferative diagnoses
(P-value comparing relative LTL in women with hyperpla-
sia versus in-situ/invasive cancers = 0.71). However,
women with proliferative disease had longer (unadjusted)
mean relative LTL compared with those with non-
proliferative diagnoses (Table 1; 1.6 (Standard deviation
(SD) = 0.9) vs. 1.2 (0.6); P = 0.002). After adjustment for
age and BMI, relative LTL was associated with a signifi-
cant increased risk of proliferative disease (Odds Ratio
(OR) = 2.46 per one unit increase of relative LTL, 95 % CI:
1.47, 4.42; Table 2). This relationship persisted when
examining the association between relative LTL and in-
situ/invasive cancer diagnoses versus non-proliferative
disease (OR = 1.98 per one unit increase of relative LTL,
95 % CI: 1.07, 4.14). Similar odds ratios were observed
after further adjustment for age at first birth and use of
menopausal hormone therapy.
Relative LTL was weakly and inversely correlated with
age in women with proliferative and non-proliferative
diagnosis (Fig. 1). After adjustment for age, longer relative
LTL was associated with higher BMI, although this trend
was statistical significant only in women with non-
proliferative diagnosis (Table 3; P = 0.03). We did not find
relative LTL to be associated with other risk factors such
as age at menarche, parity, age at first birth, menopausal
status, age at menopause or first degree family history of
breast cancer. There was a suggested association between
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diagnosis1 (N = 141)
Women with non-proliferative
diagnosis2 (N = 54)
P-value§
Age (years), mean (SD) 50.6 (6.4) 51.4 (6.4) 48.5 (6.2) 0.005
Age (years), n (%) 0.040
< 45 38 (19.5) 21 (14.9) 17 (31.5)
45–49 51 (26.2) 36 (25.5) 15 (27.8)
50–54 53 (27.2) 41 (29.1) 12 (22.2)
≥ 55 53 (27.2) 43 (30.5) 10 (18.5)
Race/Ethnicity, n (%) 1.00
White, non-Hispanic 184 (94.4) * *
Non-White 11 (5.6) * *
Education, n (%) 0.970
High school or less 29 (14.9) 21 (14.9) 8 (14.8)
Some college 34 (17.4) 24 (17.0) 10 (18.5)
College graduate or more 132 (67.7) 96 (68.1) 36 (66.7)
Age at menarche (years), n (%) 0.476
≤ 12 75 (39.1) 57 (40.7) 18 (34.6)
13 68 (35.4) 46 (32.9) 22 (42.3)
≥ 14 49 (25.5) 37 (26.4) 12 (23.1)
Parity, n (%) 0.280
Nulliparous 49 (25.1) 32 (22.7) 17 (31.5)
Parous 146 (74.9) 109 (77.3) 37 (68.5)
Age at first birth¶ (years), n (%) 0.639
< 30 105 (71.9) 80 (73.4) 25 (67.6)
≥ 30 41 (28.1) 29 (26.6) 12 (32.4)
Menopausal status, n (%) 0.103
Premenopausal 125 (64.1) 85 (60.3) 40 (74.1)
Postmenopausal 70 (35.9) 56 (39.7) 14 (25.9)
Age at menopause (years), n (%) 0.873
< 45 12 (19.7) 9 (18.8) 3 (23.1)
45–49 17 (27.9) 13 (27.1) 4 (30.8)
≥ 50 32 (52.5) 26 (54.2) 6 (46.2)
Menopausal hormone therapy use‡, n (%) 0.039
Never 37 (52.9) 26 (46.4) 11 (78.6)
Ever 33 (47.1) 30 (53.6) 3 (21.4)
Body mass index (kg/m2), mean (SD) 25.9 (5.4) 25.8 (5.5) 25.9 (5.2) 0.649
Body mass index (kg/m2), n (%) 0.158
< 25.0 103 (52.8) 78 (55.3) 25 (46.3)
25.0–29.9 53 (27.2) 33 (23.4) 20 (37.0)
≥ 30 39 (20.0) 30 (21.3) 9 (16.7)
First degree family history of breast cancer, n (%) 0.891
No 144 (73.8) 105 (74.5) 39 (72.2)
Yes 51 (26.2) 36 (25.5) 15 (27.8)
Primary pathologic diagnosis, n (%) –
Bodelon et al. BMC Cancer  (2015) 15:823 Page 5 of 12
longer relative LTL and use of postmenopausal hormone
therapy (P = 0.048).
Linear regression models evaluating the relation be-
tween MD and relative LTL were adjusted for age and
BMI, which were inversely associated with percent
volumetric and area MD measures in the entire study
population as well as in women with proliferative and
non-proliferative diagnoses (data not shown). MD was
not associated with relative LTL in our study population;
this was true irrespective of the measure of MD (percent
dense volume or area, absolute dense volume or area, and
total breast volume or area) or biopsy diagnosis (Table 4).
Similar results were obtained when modeling relative LTL
as a continuous variable (data not shown).
Discussion
In this population of women ages 40–65 undergoing
diagnostic image-guided biopsy, relative LTL was not as-
sociated with mammographic density. However, we
Table 1 Characteristics of women referred to an image-guided breast biopsy, by biopsy diagnosis (Continued)
Benign 42 (21.5) – 42 (77.8)
Other discrete non-proliferative diagnosis 12 (6.2) – 12 (22.2)
Hyperplasia 110 (56.4) 110 (78.0) –
In-situ carcinoma 22 (11.3) 22 (15.6) –
Invasive carcinoma 9 (4.6) 9 (6.4) –
Mammographic density measure¥, mean (SD)
% density (volume) 41.4 (21.5) 41.6 (20.9) 41.1 (23.0) 0.692
Dense volume (cm3) 193.5 (93.8) 195.1 (99.7) 189.2 (76.7) 0.992
Total breast volume (cm3) 603.8 (389.8) 607.8 (407.0) 593.3 (344.1) 0.776
% density (area) 30.6 (21.0) 30.0 (20.9) 32.1 (21.5) 0.539
Dense area (cm2) 35.9 (26.7) 35.3 (26.0) 37.6 (28.8) 0.886
Total breast area (cm2) 141.2 (69.3) 143.9 (72.7) 134.2 (59.3) 0.655
Relative leukocyte telomere length, mean (SD)
Overall 1.5 (0.8) 1.6 (0.9) 1.2 (0.6) 0.002
Benign 1.2 (0.5) – 1.2 (0.5)
Other discrete non-proliferative diagnosis 1.3 (1.0) – 1.3 (1.0)
Hyperplasia 1.6 (0.8) 1.6 (0.8) –
In-situ carcinoma 1.8 (1.2) 1.8 (1.2) –
Invasive carcinoma 1.4 (0.7) 1.4 (0.7) –
SD Standard deviation
*For race, categories contained cell counts less than 5; data are not presented in order to maintain participant confidentiality
1Diagnosis of hyperplasia, in-situ or invasive carcinomas
2Diagnosis of benign or other discrete non-proliferative diagnosis
§P-value comparing proliferative and non-proliferative disease. P-value based on Wilcoxon rank-sum test for continuous variables and a χ2 test for categorical
variables; for cells with values ≤5, we used the Fisher’s exact test
¶Restricted to parous women
‡Restricted to post-menopausal women
¥MD measures in breast contralateral to the primary pathologic diagnosis
The bolded numbers indicate statistical significance results at the 5 % level
Table 2 Associations of relative leukocyte telomere length (LTL) with proliferative diagnoses
Women with proliferative diagnosis1
(N = 141)Mean (SD)
Women with non-proliferative diagnosis2
(N = 54)Mean (SD)
OR (95 % CI)* OR (95 % CI)**
Relative LTL 1.6 (0.9) 1.2 (0.6) 2.46 (1.47, 4.42) 2.41 (1.43, 4.38)
Women with in situ or invasive cancer
diagnosis(N = 31)Mean (SD)
Women with non-proliferative diagnosis2
(N = 54)Mean (SD)
Relative LTL 1.7 (1.1) 1.2 (0.6) 1.98 (1.07, 4.14) 1.70 (0.86, 3.76)
SD Standard deviation
1Diagnosis of hyperplasia, in-situ or invasive carcinomas
2Diagnosis of benign or other discrete non-proliferative diagnosis
*Adjusted for age (continuous) and BMI (continuous)
**Adjusted for age (continuous), BMI (continuous), age at first birth (nulliparous/<30/≥30) and menopausal hormone therapy (premenopausal/postmenopausal
ever/ postmenopausal never)
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observed a novel association between longer relative
LTL and proliferative biopsy diagnoses.
Different measures of MD have advantages and limita-
tions [37]; therefore, we explored the relation between
relative LTL and MD using quantitative volume and area
measures of MD. However, we found similar results irre-
spective of the MD measure used. As both MD and LTL
are thought to, at least in part, reflect cellular prolifera-
tion in response to stimulation by hormones and growth
factors, we had hypothesized that MD and relative mean
LTL would be associated with one another. The ob-
served null finding suggests that the biological determi-
nants of MD and LTL differ. Notably, longer exposure to
endogenous estrogen has been found to be related to
longer telomeres [15], while support for a role of circu-
lating estrogens in mammographic density is limited
[38]. However, data suggest that elevated insulin growth
factor-I (IGF-I) may be associated with both longer LTL
[39] and with higher MD [3], whereas obesity is posi-
tively associated with IGF-I levels and negatively associ-
ated with MD. Interestingly, determinants of IGF family
members have a strong, yet incompletely defined
heritable component [40], like MD [7]. It is plausible
that relative mean LTL is not a valid surrogate for telo-
mere length in the breast. However, telomere length is
highly heritable [41] and it is thought to have similar at-
trition rates in leukocytes and somatic tissues [42, 43].
The few studies examining associations between rela-
tive LTL and breast cancer risk factors in women with-
out breast cancer have reported shorter telomeres with
older age and higher BMI [11, 13, 44]; a relation between
longer telomeres with increased number of reproductive
years and age at menopause has been reported in some
[12, 15], but not all [16], studies. Among the relatively
narrow age range of women in our study, we observed a
suggestive, albeit not statistically significant, inverse as-
sociation between age and LTL. In contrast to prior find-
ings [11, 13, 44], we found that relative LTL tended to
increase with increasing BMI. While the reasons for this
disparate finding are unclear, our inclusion criteria for
this analysis may have led to an over-representation of
leaner women; however, this association could also be
due to chance as a consequence of the number of tests
performed. Although we did not observe an association
Fig. 1 Relationship between relative leukocyte telomere length (LTL) and age by biopsy diagnosis. Individual LTL measurements (black) and linear
regression fit to the individual measurements (grey). a Relationship between LTL and age in women with proliferative diagnosis (N = 141);
Spearman’s correlation coefficient: −0.12 (P = 0.14). b Relationship between LTL and age in women with non-proliferative diagnosis (N = 54);
Spearman’s correlation coefficient: −0.16 (P = 0.24)
Bodelon et al. BMC Cancer  (2015) 15:823 Page 7 of 12
Table 3 Age-adjusted geometric mean of relative leukocyte telomere length (LTL) in relation to participant characteristics





Characteristics Mean LTL§ (95 % CI) § Mean LTL§ (95 % CI) § Mean LTL§ (95 % CI) §
Age (years) 0.817
< 45 1.27 (1.05, 1.55) 1.47 (1.13, 1.91) 1.07 (0.80, 1.42)
45–49 1.35 (1.14, 1.60) 1.47 (1.20, 1.80) 1.10 (0.81, 1.50)
50–54 1.39 (1.17, 1.64) 1.46 (1.21, 1.77) 1.16 (0.82, 1.64)
≥ 55 1.23 (1.04, 1.45) 1.31 (1.09, 1.58) 0.94 (0.65, 1.37)
P-trend 0.774 0.423 0.745
Body mass index (Kg/m2) 0.194
< 25.0 1.24 (1.10, 1.39) 1.35 (1.18, 1.55) 0.93 (0.73, 1.17)
25.0–29.9 1.29 (1.09, 1.52) 1.44 (1.17, 1.78) 1.09 (0.83, 1.42)
≥ 30 1.56 (1.29, 1.90) 1.57 (1.26, 1.96) 1.56 (1.05, 2.31)
P-trend 0.058 0.248 0.030
Age at menarche (years) 0.743
≤ 12 1.26 (1.09, 1.45) 1.33 (1.13, 1.57) 1.01 (0.74, 1.37)
13 1.36 (1.17, 1.58) 1.53 (1.28, 1.83) 1.08 (0.83, 1.41)
≥ 14 1.33 (1.11, 1.58) 1.43 (1.17, 1.75) 1.08 (0.76, 1.53)
P-trend 0.613 0.530 0.787
Parity 0.739
Parous 1.30 (1.17, 1.43) 1.39 (1.24, 1.55) 1.07 (0.88, 1.30)
Nulliparous 1.35 (1.14, 1.61) 1.53 (1.23, 1.89) 1.08 (0.81, 1.44)
Age at first birth (years)* 0.744
< 30 1.21 (1.08, 1.37) 1.30 (1.13, 1.50) 1.00 (0.79, 1.26)
≥ 30 1.51 (1.24, 1.83) 1.66 (1.31, 2.10) 1.28 (0.90, 1.81)
P-trend 0.066 0.084 0.246
Menopausal status 0.361
Premenopausal 1.37 (1.19, 1.57) 1.40 (1.18, 1.66) 1.22 (0.98, 1.51)
Postmenopausal 1.21 (0.98, 1.50) 1.45 (1.15, 1.82) 0.74 (0.47, 1.17)
Age at menopause (years) 0.221
< 45 1.37 (1.03, 1.84) 1.79 (1.30, 2.46) 0.67 (0.39, 1.17)
45–49 1.19 (0.94, 1.52) 1.28 (0.99, 1.66) 1.18 (0.68, 2.05)
≥ 50 1.24 (1.04, 1.48) 1.31 (1.09, 1.58) 0.80 (0.52, 1.22)
P-trend 0.655 0.166 0.654
Menopausal hormone therapy use‡ 0.461
Never 1.13 (0.95, 1.35) 1.26 (1.02, 1.57) 0.89 (0.60, 1.34)
Ever 1.49 (1.22, 1.80) 1.50 (1.23, 1.84) 1.10 (0.60, 2.01)
First degree family history of breast cancer 0.883
No 1.25 (1.13, 1.38) 1.35 (1.20, 1.51) 1.03 (0.85, 1.25)
Yes 1.50 (1.27, 1.78) 1.64 (1.34, 2.00) 1.19 (0.87, 1.61)
1Diagnosis of hyperplasia, in-situ cancer or invasive cancer
2Diagnosis of benign or other discrete non-proliferative diagnosis
§Based on linear regression with the log-transformed of the relative telomere length as outcome. Results are back-transformed. All characteristics were adjusted
for age (continuous) and BMI (continuous), except age and BMI respectively
¥P-value based on a Wald test in the regression model corresponding to an interaction term of the proliferative disease variable times the corresponding variable
(coded in continuous form)
*Restricted to parous women
‡Restricted to post-menopausal women
The bolded numbers indicate statistical significance results at the 5 % level
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Table 4 Age- and BMI-adjusted means of mammographic density (MD) in the breast contralateral to the primary pathologic diagnosis in relation to relative LTL
All women(N = 195) Proliferative diagnosis1(N = 141) Non-proliferative diagnosis2 (N = 54)
Measure of MD Binary LTL¶ Mean MD§ (95 % CI)§ Mean MD§ (95 % CI)§ Mean MD§ (95 % CI)§
% density (volume) <1.20 37.81 (34.43, 41.34) 38.70 (34.47, 43.18) 36.48 (30.84, 42.59)
≥1.20 39.22 (36.58, 41.94) 39.07 (36.15, 42.12) 39.57 (33.69, 45.93)
P-trend 0.529 0.89 0.475
Dense volume (cm3) <1.20 182.28 (164.16, 201.35) 185.62 (162.26, 210.55) 175.14 (146.99, 205.75)
≥1.20 185.24 (171.22, 199.81) 184.83 (168.77, 201.63) 188.37 (159.13, 220.08)
P-trend 0.805 0.958 0.540
Total breast volume (cm3) <1.20 538.44 (487.35, 592.08) 538.35 (472.00, 609.05) 531.91 (452.82, 617.38)
≥1.20 549.25 (509.65, 590.33) 548.35 (502.20, 596.52) 559.27 (478.09, 646.82)
P-trend 0.749 0.814 0.649
% density (area) <1.20 26.98 (23.15, 31.11) 25.99 (21.21, 31.26) 28.84 (22.38, 36.12)
≥1.20 26.25 (23.34, 29.33) 25.92 (22.61, 29.46) 27.27 (20.99, 34.36)
P-trend 0.774 0.983 0.748
Dense area (cm2) <1.20 32.96 (27.71, 38.65) 32.22 (25.83, 39.31) 34.20 (24.87, 44.00)
≥1.20 30.97 (27.06, 35.15) 30.79 (26.46, 35.45) 31.62 (22.68, 42.04)
P-trend 0.566 0.729 0.718
Total breast area (cm2) <1.20 132.35 (122.72, 142.36) 135.33 (122.76, 148.52) 126.28 (111.12, 142.40)
≥1.20 133.99 (126.56, 141.64) 135.66 (127.01, 144.60) 129.33 (113.98, 145.64)
P-trend 0.796 0.967 0.788
1Diagnosis of hyperplasia, in-situ cancer or invasive cancer
2Diagnosis of benign or other discrete non-proliferative diagnosis
§Based on a linear regression using square root of the density measure as outcome. Results are back-transformed. Adjusted for age (continuous) and BMI (continuous)











between relative LTL and age at menopause, our find-
ings were suggestive of a positive association between
LTL and ever use of menopausal hormone therapy, par-
ticularly among women with non-proliferative diagnoses.
A previous study of postmenopausal women found that
long-term users of hormone therapy had longer telo-
meres than never users [14], a finding which is also sup-
ported by in vitro experiments [45–47]. Results from
these experimental studies suggest that there is an estro-
gen response element (ERE) located in the promoter re-
gion of the telomerase coding gene. In the presence of
estrogen, the ERE induces transcriptional activation of
telomerase [30, 46], which may result in the elongation
of the telomeres.
In this population, we found that women with prolifer-
ative disease had longer relative LTL than women with
non-proliferative disease. Women with different prolifer-
ative diagnoses (hyperplasia vs. in situ cancer vs. cancer)
had similar mean LTL. Our study involved participants
representing a range of breast biopsy diagnoses, which
makes comparisons with prior studies that included a
healthy control group challenging. Healthy control
groups may include subjects with proliferative but non-
cancer diagnoses, which are related to breast cancer risk.
Nevertheless, our findings are consistent with some epi-
demiologic studies that have found that longer LTL is
associated with increased breast cancer risk [17–21], but
not with others that have observed inverse [24, 27, 28]
or null [22, 23, 25, 26] associations. Although the associ-
ation between longer relative LTL and breast cancer risk
may seem counter-intuitive, telomerase, a reverse tran-
scriptase that is able to synthesize telomeric DNA, may
be upregulated in women with proliferative diagnoses in
order to compensate for the shortening of telomeres re-
lated to their proliferative disease [48]. In addition, the
upregulation of telomerase may allow cells to delay cell
cycle arrest normally initiated by telomere loss, with
additional potential for mutagenesis [20, 21].
A strength of our study was the use of quantitative,
reliable density measures that have been validated with
respect to breast cancer risk. Limitations include the
relatively small sample size and narrower age range of
participants than in most prior studies of LTL [49]. It is
possible that an association between relative LTL and
MD could be observed in a population with greater vari-
ation in mean LTL. Finally, we selected women whose
breast tissues contained TDLUs suitable for future telo-
mere length assessment in relation to TDLUs. It is
known that presence of TDLUs is associated with ele-
vated mammographic density [50] and therefore this
select group of women may not be representative of the
general population of women referred to breast biopsy.
While it is possible that the method we used to select
participants for this analysis may have obscured an
association between relative LTL and MD, when we
compared the distribution of MD measures for the
women in our analysis with the rest of the study popula-
tion, the age- and BMI-adjusted mean density measures,
as well as the range of MD measures, between the two
populations were similar.
Conclusions
This is the first study to examine the relationship be-
tween MD and relative LTL, and importantly, in a popu-
lation that may be at higher risk of breast cancer, for
which biomarkers of risk may be critical. While relative
LTL was not associated with MD, we found that longer
relative LTL was associated with proliferative lesions
among women undergoing diagnostic image-guided
biopsy. This finding suggests that LTL may be a marker
of risk for proliferative pathology among women with
abnormal breast imaging prompting a biopsy. Additional
studies with larger populations and broader age ranges
are warranted.
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